Inex/Enzon’s Marqibo Will Get Oncologic Advisory Cmte. Review Dec. 1, Firms Say
This article was originally published in The Pink Sheet Daily
Executive Summary
The sponsors are seeking a monotherapy indication for treatment of relapsed aggressive non-Hodgkin’s lymphoma in patients previously treated with at least two combination chemotherapy regimens. The NDA's user fee date is Jan. 15.